

Cover Story
Conversation with The Cancer Letter
By Claire Marie Porter and Paul Goldberg
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
Cancer Policy
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Charles Rudin named cancer center director at MSK
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure
- Marcel van den Brink: Microbiome research is now in “critical phase” where evidence points to therapeutic use
- NCI’s Letai gets softball questions from Senate appropriators at an otherwise contentious hearing
















